Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3k3a-Apc, a Recombinant Variant of Human Activated Protein C, in Combination With Tissue Plasminogen Activ

Annals of Neurology - United States

doi 10.1002/ana.25383